Report title: BioRexis Pharmaceutical Corporation - Portfolio Company Report
from Thomson Financial Venture Economics
published Jun 20, 2009

Price $24.00 available for immediate download
Report Overview
 
About Thomson Financial Venture Econ...

Develops protein engineering for improved biologics. The Company is specialized in the production of therapeutic proteins and peptides with longer duration of activity to achieve reduced dose, improved safety and cost effectiveness. BioRexis' broad technology platform enables cost-efficient production of high value proprietary biopharmaceuticals by genetically engineering protein and peptide drugs into the scaffold of our proprietary carrier protein, significantly enhancing half-life, efficiency, safety, and patient compliance and convenience, while reducing the cost of treatment. BioRexis is able to also apply this proprietary protein engineering technology to replace monoclonal antibodies with our proprietary Trans-bodies that can be produced efficiently and cost effectively in yeast expression systems. ; Develops protein engineering for improved biologics.

Report Type: This research report shows venture capital financing information for this specific company.
Executives Listed: 12
Number of Investing Funds: 9
Free Sample: Click Here to Download
Format:
PDF Adobe Acrobat


Price: $24.00



  Can't Decide?

Purchasing premium research sight unseen can be intimidating. At Alacra we want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.